Kolkata: Awareness about the need to shed weight fast is proliferating fast. And riding this trend, Eli Lilly’s new weight-loss therapy Mounjaro has limbed to the top of pharma sales in India in October according to value, reports state. In its way to the top, its has overtaken GSK’s antibiotic Augmentin. Mounjaro, which is an injectable, has sold Rs 100 crore in the month of October alone, according to research firm Pharmarack.

In comparison, Augmentin sold Rs 80 crore in October. However, volumewise Augmentin outsold Mounjaro. It sold 58 lakh units compared to 85,000 units of the weight loss therapy. Mounjaro was launched in March. It is said to rein in high blood sugar and slow down digestion.

Cost of treatment in India

Mounjaro could cost an user anywhere between Rs 14,000 and Rs 2

See Full Page